Investing

0 240
Izea Inc IZEA Stock News

Izea Inc (NASDAQ: IZEA)

Izea is having an overwhelmingly strong day in the market today, and recently, the gains got so big that the stock was halted for a few minutes. This prompted our partners at Trade Ideas to alert us of the movement, and prompted the CNA Finance team to start digging to see what was happening. At the moment (1:59), IZEA is trading at $4.32 per share after a gain of $1.27 per share or 41.59% thus far today.





What’s Going On With IZEA

As soon as we received the alert, the CNA Finance team went to work to see why Izea was making a run for the top. The truth is that there’s simply not much out there. The one thing that we found was that the company plans on reporting its earnings tonight after the closing bell. So, considering the lack of data out there, we have to assume that the gains are ultimately the result of excitement ahead of earnings.




What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on IZEA. In particular, we’ll be watching for the company’s earnings report, and we hope that the performance justifies the massive gains that we’ve seen on the stock this afternoon. Nonetheless, we’ll continue to keep a close eye on the stock and bring the news to you as it breaks!

What Do You Think?

Where do you think IZEA is headed moving forward? Join the discussion in the comments below!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Pixabay]

DryShips Inc. DRYS Stock News

DryShips Inc. (NASDAQ: DRYS)

DryShips is having an overwhelmingly strong day in the market today, following up on the strong gains that we saw on the stock yesterday. In fact, our partners at Trade Ideas have been pinging us with alert after alert on this thing! At the moment, DRYS is trading at $1.52 per share after a gain of $0.12 per share (8.57%) thus far today.





What Happened With DRYS Yesterday

As mentioned above, yesterday proved to be an overwhelmingly strong day in the market for DryShips, and for good reason. The company announced that it had acquired four new capesize vessels. Two of these vessels will be operating on fixed charters. This is overwhelmingly positive news, as fixed charters help to reduce the company’s risk by reducing exposure to volatility in shipping rates. Also, with the capesize index showing that rates in the region are on their way up, this could prove to be an overwhelmingly profitable move for the company.




The Rally Continues As Morgan Stanley Issues Commentary On Dry Bulk Shipping

On top of the positive news released by DryShips yesterday, the stock got another boost from Morgan Stanley this morning. While the firm didn’t mention DRYS in particular, their statements definitely helped to boost the stock. In fact, Morgan Stanley analyst Fotis Giannakoulis issued bullish commentary on the entire dry bulk industry.

Ultimately, Giannakoulis believes that as we continue to see increased dependence on important Iron Ore in China and domestic output continues to subside, shipping demand will continue to increase, driving stock prices in the industry higher.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be watching DRYS incredibly closely, along with others in the shipping sector. In particular, we’re interested in learning more about the 4 new ship acquisitions and seeing those ships in action, driving revenue for the company. We’ll also be watching Chinese iron ore demand, as that plays a big role in the industry as a whole. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Pixabay]

0 952

Diffusion Pharmaceuticals Inc (NASDAQ: DFFN)

Diffusion Pharmaceuticals was off to a relatively normal day in the market today. However, that all changed minutes ago, when the company was awarded a new key patent. As a result, the stock spiked dramatically, prompting our partners at Trade Ideas to send the alert and the CNA Finance team to start digging. At the moment (11:30), DFFN is trading at $4.52 per share after a gain of $1.78 per share (65.03%) thus far today.





DFFN Awarded New Patnet

As mentioned above, Diffusion Pharmaceuticals exploded in value minutes ago as a new patent was awarded to the company. The patent relates to trans-carotenoid salt compounds and involves the method of making them, methods for solubilizing them, and uses of the carotenoid salt compounds themselves. In particular, the compounds are useful in improving diffusivity of oxygen between red blood cells and body tissues in mammals, including humans.




What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on DFFN. In particular, we’re interested in following the company through the process of growth, and we will be digging further into this patent for more details. We’ll continue to follow the story closely and bring you the news as it breaks!

What Do You Think?

Where do you think DFFN is headed moving forward? Join the discussion in the comments below!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Pixabay]

0 1956
Accenture Plc ACN Stock News

Accenture Plc (Germany) (NYSE: ACN) | Oracle Corporation (NYSE: ORCL)

Accenture was off to a relatively normal day in the market today. That is until minutes ago, when the stock spiked as the result of a potential takeover. As soon as the stock spiked, our partners at Trade Ideas alerted us to the movement, prompting us to do some digging. At the moment (11:11), ACN is trading at $121.08 per share after a gain of $1.69 per share (1.42%) thus far today.





ORCL Is Interested In Taking Over ACN

As soon as we received the alert, the CNA Finance team started digging and found out that the reason for the gains has to do with a potential acquisition. In fact, a story just broke stating that Oracle has hired global specialists to explore the possibility of buying the multi-billion dollar Accenture.




According to the reports, Oracle hired a team of consultants to explore synergies that could be created if the company did, indeed, acquire ACN. However, don’t look for anything to happen quickly. According to the reports, the work is in its early stages. In fact, it was said that “If buying Accenture was a 100 metre race, Oracle is at the 10 to 10 metre stage now.”

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on both ACN and ORCL. In particular, we’ll be following the process with regard to the potential acquisition. After all, this could mean a massive return of value for shareholders on both sides. We’ll continue to follow the story closely and bring you the news as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Flickr]

0 1016
Regeneron Pharmaceuticals Inc REGN Stock News

Regeneron Pharmaceuticals Inc (NASDAQ: REGN)

Regeneron Pharmaceuticals wasn’t having the best of days in the market today. In fact, the stock has been sliding all day. That is, until the stock was halted at 10:56 while trading at $376.99 per share after a loss of $6.69 per share (1.74%) thus far today. As soon as the stock was halted, our partners at Trade Ideas alerted us, prompting some digging into the story. Here’s what we’ve found so far….





Up To Date Data On The REGN Halt

At the moment, we don’t know much, considering that the stock was halted less than 4 minutes ago. However, we do know that the halt is a news pending halt. This means that trading was stopped because big news is on the horizons.




Many on Twitter (including Adam Feuerstein) are suggesting that the halt is related to a coming drug approval. However, the company has not confirmed, nor can they. After all, the stock is quiet during a news pending halt until the big news is officially released to the entire investing community.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on REGN. In particular, we’re interested in seeing if a new drug approval is the reason for the halt. We will continue to follow the story and update this article as it breaks. Stay tuned!

Update 11:36: As many suggested, the halt is the result of a drug approval. Seconds ago, it was announced that Dupixent was approved. The stock is still halted and the data is still very new. We will continue to follow the story closely and bring it to you as it breaks!

Update 11:46: REGN to resume trading at 12:05 ET. Be ready for some big movement!

Update 11:49: After reading through the label, available here, it looks very clean. In fact, it looks like REGN and SNY got everything they wanted from the FDA!

Update 12:05: REGN reopens in the green, the stock is currently trading at $385.05 per share, but is likely to climb far higher in the minutes and hours to come!

What Do You Think?

Where do you think REGN is headed? Join the discussion in the comments below!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Pixabay]

General Motors Company GM Stock News

General Motors Company (NYSE: GM)

General Motors was off to an overwhelmingly strong run in the market minutes ago, prompting our partners at Trade Ideas to alert us of the movement. The run was caused by news that Greenlight Capital made a request to unlock shareholder value through a split of the shares. However, as soon as the story broke, we saw a key reminder that investors are often the last to know. At the moment GM is trading at $35.53 per share after a gain of $0.82 per share or 2.36% thus far today.





Greenlight Requests A GM Share Split

In a plan announced today, Greenlight Capital said it reached out to General Motors in order to request a split to the shares. The split would create two classes, one that receives dividends and one that would participate in remaining earnings and cash flows as well as future growth of the company. In a statement, David Einhorn, President of Greenlight Capital, had the following to say…




As significant, long-term shareholders, we believe in GM’s strong earnings potential. Our plan would unlock significant value and lower GM’s cost of capital. It would provide the company complete strategic flexibility without adding any default, refinancing, or balance sheet risk. We encourage our fellow GM shareholders to carefully review the presentation and to urge GM’s management and Board to adopt this compelling plan.

A Quick Response From GM

Apparently, this proved to be one of those, investors are last to know, cases. In fact, shortly after the news broke that Einhorn wanted a share-split, it was announced that GM had several meetings with Einhorn with regard to the split over the course of several months. They have decided after careful consideration to reject the offer. So, essentially, we are now learning about the offer because Greenlight Capital needs the backing of more shareholders to force the split.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be watching GM stock incredibly closely. In particular, we’re watching to see if more shareholders get behind Greenlight Capital, and if they can create such a buzz around the idea that the company is forced to move forward. Nonetheless, we’ll continue to follow the story closely and bring you the news as it breaks!

Update: GM responded to Greenlight Capital saying that it expects to return $7 billion to shareholders in the year 2017!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikimedia]

0 646
Catalyst Biosciences Inc CBIO Stock News

Catalyst Biosciences Inc (NASDAQ: CBIO)

Catalyst Biosciences is having an overwhelmingly strong day in the market today, and for good reason. The company announced that it has received approval to market a new drug in South Korea. As a result, an investor frenzy ensued, leading to massive gains and prompting our partners at Trade Ideas to alert us to the movement. At the moment (9:32), CBIO is trading at $9.35 per share after a gain of $3.98 per share (74.10%) thus far today.





CBIO Achieves Drug Approval In South Korea

As mentioned above, Catalyst Biosciences is flying in the market today, and for good reason. Early this morning, the company announced that the Korean Ministry of Food and Drug Safety has approved their Investigational New Drug Application surrounding CB 27679d/ISU304. The treatment was approved for the treatment of hemophilia, a serious bleeding disorder that can result in spontaneous bleeding episodes as well as substantially long bleeding times upon injury. In a statement, Nassim Usman, Ph.D., President and CEO at CBIO, had the following to offer:

We are very pleased with the progress we and our collaborator ISU Abxis have made in advancing this Factor IX candidate toward the clinic and we look forward to the initiation of a Phase 1/2 clinical trial next quarter… We believe that stopping bleeding is good, but preventing bleeding is better. CB 2679d/ISU304 has the properties required, including high potency, to allow for daily subcutaneous injection with the potential to achieve stable and normal Factor IX clotting levels.”




What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping an incredibly close eye on CBIO. In particular, we’re interested in following the company through the continued advancement of CB 27679d/ISU304 with regard to bringing patients to normal Factor IX clotting levels. We’re also interested in seeing how the South Korean approval of the treatment turns into revenue down the line. We’ll continue to follow the story closely and bring the news to you as it breaks!

What Do You Think?

Where do you think CBIO is headed moving forward? Join the discussion in the comments below!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 346
RXi Pharmaceuticals Corporation RXII Stock News

RXi Pharmaceuticals Corporation (NASDAQ: RXII)

RXi Pharmaceuticals is having an overwhelmingly strong day in the market today. After issuing a PR informing investors of a new patent, the stock started to climb dramatically, leading to an alert from our partners at Trade Ideas. At the moment (9:46), RXII is trading at $1.05 per share after a gain of $0.29 per share (38.17%) thus far today.





RXII Announces Receipt Of New Patent

As mentioned above, RXII is having an overwhelmingly strong day in the market today after issuing a PR that announced the receipt of a new patent. The patent was granted by the Japan Patent Office surrounding the composition of matter of sd-rxRNAs targeting connective tissue growth factor for the treatment and/or prevention of fibrotic disorders. This includes but is not limited to skin fibrosis as well as proliferative retinopathy. The patent specifically includes RXi Pharmaceuticals’ lead drug candidate RXI-109, a compound that is currently being evaluated in Phase 2 clinical trials. The patent will expire in 2031. In a statement, Pamela Pavco, PhD, Chief Development Officer at RXII, had the following to offer:




From our ongoing Phase 2 clinical trials, we have reported preliminary results indicating that the use of RXI-109 after scar revision surgery had a visible, beneficial effect on the suppression of hypertrophic scarring, at three months following revision surgery. We have also shown RXI-109 to be safe and well-tolerated in the eye in our ongoing ocular trial. This patent increases our ability to protect our novel CTGF-targeting compounds which are based on our proprietary self-delivering RNAi platform… The granting of this patent in Japan further strengthens RXi’s intellectual property estate for future commercial and regional business development opportunities for RXI-109.”

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on RXII. In particular, we’ll be following the company’s ongoing work with regard to its lead candidate RXI-109 as it continues to look more and more promising. We’ll continue to keep a close eye on the news and bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Pixabay]

0 538
Cara Therapeutics Inc CARA Stock News

Cara Therapeutics Inc (NASDAQ: CARA)

Cara Therapeutics is having a strong time in the pre-market hours this morning, and for good reason. The company released top-line data from Part A of a key clinical study, leading to investor excitement. Of course, that investor excitement pushed the stock up, prompting our partners at Trade Ideas to send the alert. At the moment (9:14), CARA is trading at $20.69 per share after a gain of $2.54 per share (13.99%) thus far today.





CARA Announces Positive Clinical Data

As mentioned above, Cara Therapeutics is having an overwhelmingly strong start to the trading session in the pre-market hours today. This is the result of positive top-line data that was released. The data came from Part A of its Phase 2/3 clinical study looking into I.V. CR845 as a treatment for itching and improved quality of life in patients with uremic puritus. The company announced that it met both its primary and secondary endpoints with regard to the study, showing significant improvements in both itching and quality of life. This is great news, as there is no approved therapy for this condition in the United States to date. In a statement, Derek Chalmers, Ph.D., D.Sc., President and CEO at CARA, had the following to offer:




We are extremely pleased with these results, where I.V. CR845 demonstrated sustained clinical and quality of life benefits in dialysis patients suffering from UP and supports the viability of this therapeutic approach for the long-term treatment of this unmet medical need. As a next step, we plan to meet with the FDA to finalize the trial design of Part B of this Phase 2/3 study and to initiate patient recruitment later this year.”

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to watch CARA incredibly closely. In particular, we’re looking forward to the company’s continued work with I.V. CR845, considering the fact that there are no approved treatments in the United States quite yet. We’ll continue to follow the story closely and bring you the news as it breaks!

What Do You Think?

Where do you think CARA is headed moving forward? Join the discussion in the comments below!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikimedia]

0 476
HTG Molecular Diagnostics Inc HTGM Stock News

HTG Molecular Diagnostics Inc (NASDAQ: HTGM)

HTG Molecular Diagnostics is having an overwhelmingly rough time in the pre-market hours. The declines are the result of news that the company filed for a secondary public offering. As a result, investors are pushing the stock down, which prompted our partners at Trade Ideas to send an alert regarding the movement. At the moment (8:58), HTGM is trading at $8.17 per share after a loss of 14.45% thus far today.





HTGM Plans Secondary Offering

As mentioned above, HTG Molecular Diagnostics is having a rough time in the pre-market hours after filing for a secondary public offering. The offering is designed for the sale of shares or common stock with a total value of $75 million.

What’s The Big Deal?

With the stock falling, many newcomers to the investing world may be asking what the deal is. Why is it that HTGM is falling on the offering? Well, the answer is relatively simple. Ultimately, if you think of a company as a big pie with each share being a piece, it becomes easier to understand. You see, to offer more shares in a secondary public offering, each piece of the pie becomes a bit smaller in a process that is known as dilution. So, investors are essentially concerned about dilution cutting into the value of the shares that they already own.




What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on HTGM. In particular, we’re interested in learning more about this offering, and how the company intends to use the funds that it raises from the offering. We’ll continue to follow the story closely and bring you the news as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Flickr]

Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 3890
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...